<DOC>
	<DOC>NCT01133873</DOC>
	<brief_summary>The purpose of this study is to determine the daily maximum tolerated dose of propoxyphene napsylate in healthy subjects.</brief_summary>
	<brief_title>Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dextropropoxyphene</mesh_term>
	<criteria>Body mass index ≥ 18 and ≤ 30 (kg/m2) Medically healthy with normal screening results, or in the case of results that are abnormal; the abnormal results are clinically insignificant (eg, medical history, physical examination, neurological assessment, vital signs, oxygen saturation, laboratory profiles) 12lead ECGs (calculations by the electrocardiograph) which have no clinically significant findings Vital signs which are within normal range No tobacco/nicotinecontaining product use for a minimum of 6 months If female, must be able to adhere to acceptable methods of contraception or be postmenopausal or surgically sterile History or presence of significant cardiovascular, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, or neurological disease History or presence of any degree of chronic obstructive pulmonary disease History of suicidal ideations or depression requiring professional intervention including counseling or antidepressant medication Any history of drug or alcohol abuse Positive drug (urine)/alcohol (breath) testing at screening or checkin Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (HCV) History of hypersensitivity or allergy to propoxyphene or any opioid compound, naloxone, naltrexone, palonosetron (Aloxi®), glycerin, senna, or bisacodyl (Dulcolax®) Use of any prescription medication (with the exception of hormonal contraceptives for females) within 2 weeks of enrollment Use of any overthecounter medication, including herbal products, within 1 week of enrollment Use of any drugs known to significantly inhibit or induce liver enzymes involved in drug metabolism [CYP P450]) within 30 days of enrollment Blood donation or significant blood loss within 30 days of enrollment Plasma donation within 7 days of enrollment Participation in another clinical trial within 30 days of enrollment Females who are pregnant or lactating Any other condition or prior therapy, which, in the opinion of the PI, would make the subject unsuitable for this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>